INT67855

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1996
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 64
Total Number 65
Disease Relevance 17.83
Pain Relevance 13.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

isomerase activity (PPIG) protein folding (PPIG) nucleoplasm (PPIG)
nucleolus (PPIG) nucleus (PPIG) cytoplasm (PPIG)
Anatomy Link Frequency
liver 5
1A2 4
plasma 3
blood 1
Atrium 1
PPIG (Homo sapiens)
Pain Link Frequency Relevance Heat
Potency 81 99.92 Very High Very High Very High
methadone 102 99.84 Very High Very High Very High
fluoxetine 97 99.74 Very High Very High Very High
sSRI 171 99.52 Very High Very High Very High
Duloxetine 115 99.52 Very High Very High Very High
pregabalin 136 99.26 Very High Very High Very High
Analgesic 19 99.20 Very High Very High Very High
withdrawal 53 99.12 Very High Very High Very High
aspirin 18 99.12 Very High Very High Very High
tramadol 6 99.12 Very High Very High Very High
Disease Link Frequency Relevance Heat
Toxicity 663 99.82 Very High Very High Very High
Injury 113 99.76 Very High Very High Very High
Arrhythmia Under Development 35 99.08 Very High Very High Very High
Head Trauma 4 98.72 Very High Very High Very High
Hepatotoxicity 63 98.48 Very High Very High Very High
Appetite Loss 10 98.36 Very High Very High Very High
Recurrence 86 98.12 Very High Very High Very High
Disorders Of Creatine Metabolism 13 98.04 Very High Very High Very High
Urological Neuroanatomy 37 97.96 Very High Very High Very High
Cv Unclassified Under Development 7 97.84 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Fluvoxamine is a substantial inhibitor of CYP1A2 and CYP2C19, and a moderate inhibitor of CYP3A3/4.
Negative_regulation (inhibitor) of CYP
1) Confidence 0.57 Published 1996 Journal Int Clin Psychopharmacol Section Abstract Doc Link 9032002 Disease Relevance 0.10 Pain Relevance 0.28
Duloxetine would not be expected to cause clinically significant inhibition of the metabolic clearance of drugs metabolised by P450 (CYP)3A, (CYP)1A2, (CYP)2C9, or (CYP)2C19, but would be expected to cause some inhibition of CYP 2D6.
Negative_regulation (inhibition) of CYP in 1A2 associated with duloxetine
2) Confidence 0.57 Published 2005 Journal Expert Opin Drug Saf Section Abstract Doc Link 16255658 Disease Relevance 0.25 Pain Relevance 0.45
The rats with protein-calorie malnutrition (PCM, 5% casein diet for a period of 4-week) were reported to exhibit 60 and 80% suppression in the hepatic microsomal cytochrome P450 (CYP) 1A2 and CYP2C11 levels, respectively, and 40-50% decreases in CYP2E1 and CYP3A1/2 levels compared to control (23% casein diet for a period of 4-week) based on Western blot analysis.
Negative_regulation (suppression) of CYP in 1A2 associated with appetite loss
3) Confidence 0.57 Published 2004 Journal Arch. Pharm. Res. Section Abstract Doc Link 15356995 Disease Relevance 0.17 Pain Relevance 0
It is an inhibitor of cytochrome P450 (CYP) 2D6 and other CYP enzymes, which increases the potential for drug interactions.
Negative_regulation (inhibitor) of CYP
4) Confidence 0.57 Published 2004 Journal Expert Opin Drug Saf Section Abstract Doc Link 15335304 Disease Relevance 0.08 Pain Relevance 0.45
OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6.
Negative_regulation (inhibitor) of CYP
5) Confidence 0.57 Published 2007 Journal Eur. J. Clin. Pharmacol. Section Abstract Doc Link 16680561 Disease Relevance 0 Pain Relevance 0.08
The selective serotonin reuptake inhibitors (SSRIs) paroxetine, sertraline, and fluoxetine have varying degrees of potency in inhibiting the hepatic cytochrome P450 (CYP) 2D6 enzyme.
Negative_regulation (inhibiting) of CYP associated with ssri, potency and fluoxetine
6) Confidence 0.57 Published 2002 Journal J Clin Psychopharmacol Section Abstract Doc Link 11910262 Disease Relevance 0 Pain Relevance 0.48
Relative to other SSRIs, fluvoxamine is a weak inhibitor of cytochrome P450 (CYP) 2D6, a moderate inhibitor of CYP2C19 and CYP3A4 and a potent inhibitor of CYP1A2.
Negative_regulation (inhibitor) of CYP associated with ssri
7) Confidence 0.57 Published 2000 Journal Drugs Section Abstract Doc Link 11085201 Disease Relevance 0.31 Pain Relevance 0.25
Nefazodone is a weak inhibitor of cytochrome P450 (CYP) 2D6 and does not inhibit CYP1A2.
Negative_regulation (inhibitor) of CYP
8) Confidence 0.57 Published 1997 Journal Clin Pharmacokinet Section Abstract Doc Link 9342502 Disease Relevance 0 Pain Relevance 0.10
The reason of this effect is that tramadol is the substrate and clarithromycin is the inhibitor of the CYP 3A4 enzyme.
Negative_regulation (inhibitor) of CYP associated with tramadol
9) Confidence 0.57 Published 2010 Journal Neuropsychopharmacol Hung Section Abstract Doc Link 20305307 Disease Relevance 0.24 Pain Relevance 0.25
As fluoxetine is a potent inhibitor of cytochrome P450 (CYP) 2D6, these results also provide indirect evidence for an involvement of CYP2D6 in the metabolism of haloperidol.
Negative_regulation (inhibitor) of CYP associated with fluoxetine
10) Confidence 0.57 Published 1997 Journal Pharmacol. Res. Section Abstract Doc Link 9264051 Disease Relevance 0.06 Pain Relevance 0.47
Because of its potential to prolong corrected QT (QTc) intervals, ranolazine should not be used in patients with hepatic impairment, those with QTc prolongation, or those taking drugs known to prolong QTc intervals or drugs that are potent CYP 3A4 inhibitors.
Negative_regulation (inhibitors) of CYP
11) Confidence 0.42 Published 2006 Journal Clin Ther Section Body Doc Link 17296457 Disease Relevance 0.06 Pain Relevance 0
Duloxetine should not be used in combination CYP 1A2 inhibitors or nonselective, irreversible monoamine oxidase inhibitors.
Negative_regulation (inhibitors) of CYP in 1A2 associated with duloxetine and monoamine
12) Confidence 0.42 Published 2005 Journal Expert Opin Drug Saf Section Abstract Doc Link 16255658 Disease Relevance 0.24 Pain Relevance 0.44
A daily dose of 2.5 mg is recommended for patients with moderate to severe renal impairment or those who are taking potent CYP 3A4 inhibitors.
Negative_regulation (inhibitors) of CYP
13) Confidence 0.42 Published 2010 Journal Cardiol Rev Section Abstract Doc Link 20539105 Disease Relevance 0.65 Pain Relevance 0.08
Significant drug interactions are observed when cilostazol is coadministered with other agents that inhibit cytochrome P450 (CYP) 3A4 (e.g. erythromycin or diltiazem) or CYP2C19 (e.g. omeprazole).
Negative_regulation (inhibit) of CYP
14) Confidence 0.42 Published 2003 Journal Am J Cardiovasc Drugs Section Abstract Doc Link 14727939 Disease Relevance 0.88 Pain Relevance 0.39
Some HMG CoA reductase inhibitors have the ability to inhibit the CYP 3A4 enzyme, which can result in a possible interaction if administered concomitantly with clopidogrel.
Negative_regulation (inhibit) of CYP
15) Confidence 0.42 Published 2006 Journal J. Thromb. Thrombolysis Section Abstract Doc Link 17008981 Disease Relevance 0.08 Pain Relevance 0.61
BACKGROUND: Macrolide antibiotics such as clarithromycin are potent inhibitors of the cytochrome P450 (CYP)3A4 isozyme and have the potential to attenuate the metabolism and increase blood concentrations of drugs metabolized by this pathway.
Negative_regulation (inhibitors) of CYP in blood
16) Confidence 0.42 Published 2002 Journal Clin Ther Section Abstract Doc Link 12017403 Disease Relevance 0 Pain Relevance 0.20
Combining methadone with a CYP 3A4 inhibitor increases the risk of torsades de pointes, as methadone is metabolised by this enzyme system. (4) Factors potentially predisposing patients to torsades de pointes must be analysed in each case; these include preexisting bradycardia, congenital QT prolongation, hypokalemia, and concomitant use of other drugs inducing QT prolongation. (5) This adverse effect has also been reported with levacetylmethadol (another opiate) and with heroin.
Negative_regulation (inhibitor) of CYP associated with heart rate under development, arrhythmia under development, opiate, methadone and bartter syndrome
17) Confidence 0.42 Published 2005 Journal Prescrire Int Section Abstract Doc Link 15875343 Disease Relevance 0.62 Pain Relevance 0.80
It is an inhibitor of cytochrome P450 (CYP) 2D6 and other CYP enzymes, which increases the potential for drug interactions.
Negative_regulation (inhibitor) of CYP
18) Confidence 0.41 Published 2004 Journal Expert Opin Drug Saf Section Abstract Doc Link 15335304 Disease Relevance 0.08 Pain Relevance 0.45
The deficiency in CYP 2C19 might also contribute to Atrium hepatotoxicity.
Negative_regulation (deficiency) of CYP in Atrium associated with hepatotoxicity
19) Confidence 0.41 Published 1997 Journal J. Hepatol. Section Abstract Doc Link 9204405 Disease Relevance 0.83 Pain Relevance 0.14
Thus, the genetic deficiency in a particular hepatic cytochrome P 450 isozyme (CYP 2D6) is involved in per-hexiline liver injury.
Negative_regulation (deficiency) of CYP in liver associated with injury
20) Confidence 0.41 Published 1997 Journal J. Hepatol. Section Abstract Doc Link 9204405 Disease Relevance 0.83 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox